Home ›
Ovarian Cancer Trials ›
NCT05942300
CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
This is a clinical trial using CPI-0209 in combination with Carboplatin chemotherapy followed by CPI-0209 maintenance in patients with platinum sensitive, recurrent ovarian cancer.
Trial Details
NCT ID NCT05942300
Phase PHASE1
Sponsor Lan Coffman
Status RECRUITING
Cancer Type Ovarian Cancer
Interventions
Locations (sample) Pittsburgh, Pennsylvania, United States|40.44062,-79.99589
Key Eligibility Criteria
Patients with platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer (defined as recurrent disease \> 6 months after completi… Documented disease recurrence/progression based on GCIG-RECIST Must have had at least 1 prior line of platinum-based therapy, prior bevacizumab or PARPi use are allowed. Women with germline BRCA mutations shoul… Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 with life expectancy of ≥ 3months
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Ovarian Cancer Trials on Trialify →